ZA200409091B - Process and intermediates for making non-nucleoside HIV-1 reverse transcriptase inhibitors. - Google Patents
Process and intermediates for making non-nucleoside HIV-1 reverse transcriptase inhibitors. Download PDFInfo
- Publication number
- ZA200409091B ZA200409091B ZA200409091A ZA200409091A ZA200409091B ZA 200409091 B ZA200409091 B ZA 200409091B ZA 200409091 A ZA200409091 A ZA 200409091A ZA 200409091 A ZA200409091 A ZA 200409091A ZA 200409091 B ZA200409091 B ZA 200409091B
- Authority
- ZA
- South Africa
- Prior art keywords
- group
- formula
- pyridyl
- phenyl
- furyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 15
- 239000000543 intermediate Substances 0.000 title description 15
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 title description 2
- 239000002777 nucleoside Substances 0.000 title description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 title description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 title 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 42
- 150000001875 compounds Chemical class 0.000 claims description 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- 125000004076 pyridyl group Chemical group 0.000 claims description 24
- 125000002541 furyl group Chemical group 0.000 claims description 23
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 19
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 17
- 125000001624 naphthyl group Chemical group 0.000 claims description 14
- 125000001544 thienyl group Chemical group 0.000 claims description 14
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 239000000460 chlorine Substances 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 7
- 229910052698 phosphorus Inorganic materials 0.000 claims description 7
- 239000000376 reactant Substances 0.000 claims description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052794 bromium Chemical group 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 239000011574 phosphorus Substances 0.000 claims description 5
- 239000007858 starting material Substances 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 239000011593 sulfur Substances 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 230000007062 hydrolysis Effects 0.000 claims description 4
- 238000006460 hydrolysis reaction Methods 0.000 claims description 4
- 229910052763 palladium Inorganic materials 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- UQSQSQZYBQSBJZ-UHFFFAOYSA-M fluorosulfonate Chemical group [O-]S(F)(=O)=O UQSQSQZYBQSBJZ-UHFFFAOYSA-M 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 16
- 102100034343 Integrase Human genes 0.000 description 13
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 238000006254 arylation reaction Methods 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- -1 2-(quinolinyl)oxyethyl Chemical group 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 108020000999 Viral RNA Proteins 0.000 description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical class B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 229910000085 borane Inorganic materials 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 229910052987 metal hydride Inorganic materials 0.000 description 3
- 150000004681 metal hydrides Chemical class 0.000 description 3
- 238000006894 reductive elimination reaction Methods 0.000 description 3
- 102220007331 rs111033633 Human genes 0.000 description 3
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 125000003262 carboxylic acid ester group Chemical group [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
- 230000009088 enzymatic function Effects 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 2
- NLEAIFBNKPYTGN-UHFFFAOYSA-N methyl 2-(benzenesulfonyl)acetate Chemical compound COC(=O)CS(=O)(=O)C1=CC=CC=C1 NLEAIFBNKPYTGN-UHFFFAOYSA-N 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- JXYPNRIYAMXJSE-UHFFFAOYSA-N 1,4-diazepin-6-one Chemical group O=C1C=NC=CN=C1 JXYPNRIYAMXJSE-UHFFFAOYSA-N 0.000 description 1
- HAGRVRKSGQTFKQ-UHFFFAOYSA-N 2-cyano-3-methylbutanoic acid Chemical compound CC(C)C(C#N)C(O)=O HAGRVRKSGQTFKQ-UHFFFAOYSA-N 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 101150104269 RT gene Proteins 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- YLQBEKUKMJWXMC-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopenta-2,4-dien-1-ylphosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.P[c-]1cccc1 YLQBEKUKMJWXMC-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical group CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001463 metal phosphate Inorganic materials 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BESQLCCRQYTQQI-UHFFFAOYSA-N propan-2-yl 2-cyanoacetate Chemical compound CC(C)OC(=O)CC#N BESQLCCRQYTQQI-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102220264750 rs1305455942 Human genes 0.000 description 1
- 102220012898 rs397516346 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Description
PROCESS AND INTERMEDIATES FOR MAKING NON-NUCLEOSIDE HIV-1 ) REVERSE TRANSCRIPTASE INHIBITORS v s TECHNICAL FIELD OF THE INVENTION
The invention relates to a novel process and novel intermediates for the synthesis of certain non-nucleoside reverse transcriptase inhibitors.
The disease known as acquired immune deficiency syndrome (AIDS) is caused by the human immunodeficiency virus (HIV), particularly the strain known as HIV-1. In order for HIV to be replicated by a host cell, the information of the viral genome must be integrated into the host cell’s DNA. However, HIV is a retrovirus, meaning that its genetic information is in the form of RNA. The HIV replication cycle, therefore, requires a step of transcription of the viral genome (RNA) into DNA. The transcription of the viral RNA into DNA is accomplished by an enzyme that has been aptly dubbed reverse transcriptase (RT). The HIV virion includes a copy of RT along with the viral RNA.
Reverse transcriptase has three known enzymatic functions. It acts as an RNA-dependent
DNA polymerase, as a ribonuclease, and as a DNA-dependent DNA polymerase. Acting as an RNA-dependent DNA polymerase, RT transcribes a single-stranded DNA copy of the viral RNA. Acting as a ribonuclease, RT destroys the original viral RNA, and frees the
DNA just produced from the original RNA. Finally, acting as a DNA-dependent DNA polymerase, RT makes a second, complementary DNA strand, using the first DNA strand asa template. The two strands form double-stranded DNA, which is integrated into the host cell’s genome by another enzyme called integrase. : Compounds that inhibit the enzymatic functions of HIV-1 reverse transcriptase will inhibit °. replication of HIV-1 in infected cells. Such compounds are useful in the prevention or treatment of HIV-1 infection in human subjects, as demonstrated by known RT inhibitors such as 3'-aziod-3'-deoxythymidine (AZT), 2',3'-dideoxyinosine (ddI), 2',3'- .
dideoxycytidine (ddC), d4T,3TC, nevirapine, delavirdine, efavirenz and abacavir, the RT * inhibitors thus far approved as drugs for use in the treatment of HIV infection.
Co As with any antiviral therapy, use of RT inhibitors in the treatment of HIV infection eventually leads to a virus that is less sensitive to the given drug. Resistance (reduced sensitivity) to these drugs is the result of mutations that occur in the reverse transcriptase segment of the pol gene. Several mutant strains of HIV have been characterised, and resistance to known therapeutic agents is due to mutations in the RT gene. Some of the most commonly observed mutant clinically are: the Y181C mutant, in which a tyrosine Y, at codon 181, has been mutated to a cysteine C residue, and K103N where the lysine K at position 103 has been replaced by asparagine N. Other mutants which emerge with increasing frequency during treatment with known antivirals include the single mutants
V106A, G190A, Y188C, and P236L: and the double mutants K103N/Y181C,
KO013N/P225H, K103N/V108I and K103N/L100L.
As therapy of HIV infection using antivirals continues, the emergence of new resistant strains is expected to increase. There is therefore an ongoing need for new inhibitors of
RT, with different patterns of effectiveness against the various mutants.
Of particular relevance to the present invention are the HIV-RT inhibitors disclosed by
U.S. Pat. 6,420,359. These compounds, which are all dipyrido[3,2-b:2’,3’-¢] [1,4]diazepin-6-ones bearing a 2-(quinolinyl)oxyethyl or a 2-(1-oxido-quinolinyl)oxyethyl group in the 8-position, have enhanced activity against certain clinically significant mutant strains of HIV-1. It is the object of the present invention to provide an alternative method for making the compounds disclosed by U.S. Pat. 6,420,359. , SUMMARY OF THE INVENTION
The invention provides an improved process for making compounds of the general formula ‘ I:
RY 0)
R) \
N 6 : N
I 7 . 3 4 / 8 0. \2 7a 10.2 Q 1 N / Nn | NN
R R"
M wherein:
R? is selected from the group consisting of H, F, Cl, C4 alkyl, C3. cycloalkyl and CFj; s R*is Hor Me;
R’is H, Me or Et, with the proviso that R* and R? are not both Me, and if R* is Me then R® cannot be Et;
R'! is Me, Et, cyclopropyl, propyl, isopropyl, or cyclobutyl; and
Q is selected from the group consisting of:
J : ] : —N —N 7 and j — Ng _ —N + (0) o—
H as well as pharmaceutically acceptable salts thereof.
The synthetic method of the invention commences from a starting compound of the formula II
RY 0)
R\ \
N
\ Vz —
N
NN
R R"
Hy) wherein R?, RY, R® and R'! are as defined above with respect to compounds of the formula
I and wherein X is a chlorine, iodine, or bromine, or a fluorosulfonate moiety selected from the group consisting of “OSO,F and -OSO»(CF),CF; wherein n is an integer between 0 and 10. Processes for making starting compounds of the formula II wherein X is bromine are described in U.S. Pat. 6,420,359. Compounds wherein X is other than bromine can be made by analogous methods which will be readily apparent to those of ordinary skill in the art.
It is preferred to use a compound of the formula II wherein X is bromine.
The starting compound of the formula II initially undergoes a palladium-catalyzed coupling reaction wherein it is caused to arylate a malonate or malonate surrogate of the formula III ‘ R'2 rR" ~~ am - wherein,
R'? is a cyano group or a group of the formula -COOR'¢, wherein R'* is a C-j4-alkyl ) group, a C-;.4-alkyloxy-C-4-alkyl group group phenyl, naphthyl, thiophenyl, furyl, pyridyl, imidazole or benzyl, and ) R"™ isa cyano group, a group of the formula -COOR"? (wherein R' is a C- s-alkyl group, a C-;4-alkyloxy-C-,.s-alkyl group group phenyl, naphthyl, thiophenyl, furyl, pyridyl, imidazole or benzyl), a group of the formula -SO,R'® (wherein R'® is a C-1.4-alkyl group, phenyl, furyl, pyridyl or benzyl), a group of the formula -P(O)(OR'"); (wherein R"? is phenyl, furyl or pyridyl) or a group of the formula -SOR" (wherein R'® is a C-; s-alkyl group, a C-.4-alkyloxy-C-;4-alkyl group group phenyl, naphthyl, thiophenyl, furyl, pyridyl, imidazole or benzyl).
It is preferred to employ a malonate surrogate of the formula I11 12 13
RNR (111) wherein,
R!? is a cyano group or a group of the formula —COOR'", wherein R' is a C-14-alkyl group, a C-; 4-alkyloxy-C-14-alky! group group phenyl, naphthyl, thiophenyl, furyl, pyridyl, imidazole or benzyl; and
R® is a cyano group, a group of the formula -SO,R'® (wherein R'® is a C-.s-alkyl group, phenyl, furyl, pyridyl or benzyl), a group of the formula -P(O)(OR"), (wherein R" is phenyl, furyl or pyridyl) or a group of the formula -SOR'® (wherein R'® is a C-;4-alkyl group, a C-, 4-alkyloxy-C-j4-alkyl group group phenyl, naphthyl, thiophenyl, furyl, pyridyl, imidazole or benzyl).
The reaction of the compounds of the formulas II and III takes place in an organic solvent, in the presence of a palladium catalyst, a suitable ligand and strong base. Suitable solvents are, by way of non-limiting example, toluene, ethylbenzene, xylene, DMF, DMA, NMP, . dioxane and THF, with toluene being preferred. Virtually any palladium catalyst may be used, such as, for example, Pd(OAc),, PdCl,, Pd,dba; and Pd on carbon, with Pd(OAc), being preferred. Suitable bases are, for example, the metal hydrides such as, for example,
NaH, the metal alkoxides such as, for example, t-BuOK, t-BuONa and Na-tert-amylate, the ’ metal carbonates such as, for example, Na,COj;, K2COj3 ang Cs2CO3, with NaH being preferred, and the metal phosphates such as, for example, K3;PO4. When the reactant of the formula III is a malonate (compounds wherein R'2and R'? are both carboxylic acid ester groups) then suitable ligands will be t-Bu3P, one of the ligands described and claimed in
U.S Patent 6,307,087, or a ferrocenyl phosphine such as described in U.S. Patents 6,057,456 and USP 6,072,073. When the reactant of the formula III is not a malonate, but rather a malonate surrogate (a compound wherein R'? and R"? are not both carboxylic acid ester groups) the above-mentioned ligands may be employed and, in addition, a triarylphosphine such as, by way of non-limiting example, PPh; o-Tol;P, p-Tol;P and o-
Fur;P may also be employed. In such case the preferred ligand is PPh.
The reaction is preferably carried out at elevated temperature, more preferably in the range between about 50 and 150°C.
The above described reaction, which couples the compounds of the formulas II and III, yields an intermediate of the formula IV 5
R} "\, 7 R" leSos \ VY, —
R? N 1. y (Iv) wherein RZ, RY, R® , R' I R'? and R" are as defined above.
Isolation of the intermediate of the formula IV before going on to the next process step is . optional. It has been found that a one pot synthesis wherein the intermediate IV is not isolated is quite convenient. If the intermediate IV is not isolated and the residual base isa ; metal hydride, such as NaH, then it is advisable to quench the base with an agent such as isopropyl alcohol before going on to the next step.
If the intermediate of the formula IV contains sulfur or phosphorus (because R" in the : reactant of the formula I11 was a group of the formula -SO;R"® or -P(O)(OR'®),) then the next process step is a reductive cleavage of the sulfur or phosphorus-containing group.
Methods for performing such reductive cleavage will be well known to those of ordinary skill in the art. For example, this might be accomplished by the use of Raney nickel or a dissolving metal reaction.
Subsequent to the reductive cleavage or, if the intermediate of formula IV does not contain sulfur or phosphorus, the intermediate of the formula IV is next hydrolyzed to yield a further intermediate of the formula V
RY 0
RY \
N
= AN \ ) / R'" —
NN
R Rr! (V) wherein R?, RY, R® and R'! are as defined above and R'® is <COOH or, if the reactant of formula III was a malonate and mild hydrolysis conditions are employed, R'® may additionally be a group of the formula —COOR! wherein R' is as described above. The hydrolysis may be performed in a manner that will be conventional and readily apparent to those of ordinary skill in the art. For example, it may be accomplished using an aqueous base, such as NaOH, preferably at ambient temperature or above.
The intermediates of the formulas IV and V are believed to be novel and constitute a part of the invention. . Isolation of the intermediate V before going on to the next step is preferred. ; Next, the carboxylic acid or ester intermediate of the formula V is reduced to yield an alcohol of the formula VI
. R\ AN 7
N
V7 —
R? N , iy (VD) wherein R?, R?, R® and R'' are as defined above. Reduction is carried out in a conventional manner that will be readily apparent to those of ordinary skill in the art.
Regardless of whether the intermediate of the formula V is an acid or an ester, reduction s may be accomplished using boranes, borohydrides or other metal hydrides or dissolving metal reductants, with boranes being preferred for the acids and borohydrides being preferred for the esters. If a borane is to be employed it is preferred to make it in situ from a borohydride, such as sodium borohydride, and an electrophilic reagent such as, for example HCl.
Finally, the alcohol of formula VI is converted to the final product of the formula I by a condensation reaction with a reactant of the formula
HO HO
HO
HO
{ C =x C —, =N , =N , Oo or o
This condensation may be accomplished in the manner described in U.S. Patent 6,420,359.
The nature and scope of the invention will be better appreciated from the following examples.
Example 1: Arylation of Malononitrile: Formation of Compound of Formula IV where ; 20 R2=R4=H, R5=Me, R11= ethyl, and R12=R13=CN.
A flask was charged with 10.0g tricyclic bromide (compound of formula II where
R2=R*=H, R5=Me, R11= ethyl, and X= Br; 30 mmol, 1 eq.), 0.95g triphenylphosphine (3.6 mmol, 0.12 eq.), 0.55 g Pd,dba; (0.6 mmol, 0.04 eq.), and 40 mL 1,4-dioxane. To this i mixture was then added 2.16g sodium hydride (90 mmol, 3 eq.) in portions over 15 minutes, using 40 mL 1,4-dioxane to complete the addition. A solution of 2.57g ’ malononitrile (39 mmol, 1.3 eq.) in 5 mL 1,4-dioxane was then added, and the mixture heated to 90°C. After 18h the mixture was cooled to ambient temperature and cautiously quenched with 100 mL of sat’d ammonium chloride solution. The pH was then adjusted to 6 with IN HCI, and the mixture extracted with dichloromethane. The organic solution was dried (magnesium sufate), and the solvents removed in vacuo to give 7.03g (73%) of the product as a brown oil. NMR and MS showed the desired product (Compound of Formula
IV where R2=R*=H, R’=Me, R''= ethyl, and R'>=R"=CN).
Example 2: Arylation of Diethylmalonate: Formation of Compound of Formula IV where R?=R*‘=H, R°=Me, R''= ethyl, and R'’=R"=COELt.
A S00 ml two neck round bottom flask fitted with mechanical stirrer, reflux condenser and thermocouple was purged with argon for 20 minutes, then 404 mg Pd(OAc); (1.80 mmol, 0.03 eq.), 1.08g 2-(di-t-butylphosphino)biphenyl (3.60 mmol, 0.06 eq.), and 20.0g tricyclic bromide (compound of formula II where R2=R4=H, R5=Me, R11= ethyl, and X= Br; (60.0 mmol, 1 eq.) were charged. To this mixture in an inerted flask was then added 25.5g
K3POs4 (120 mmol, 2 eq.), 100 mL PhMe, and 13.8 mL diethylmalonate (90.0 mmol, 1.5 eq.) were then added. The stirred suspension was placed in an oil bath and heated at reflux under nitrogen for 24h until the bromide was consumed by HPLC. The reaction mixture was cooled to room temperature and diluted with water (150 ml) and toluene (50 ml) was added. The mixture was stirred for 1h at room temperature until all solids had dissolved.
The two-phase solution was then transferred to a separatory funnel and the layers were separated. The aqueous layer was extracted with toluene (50 ml). The combined organic : layers were filtered through a pad of Celite and concentrated under vacuum to give a viscous oil, which was evaporated to dryness to furnish an orange solid. Silica gel ; chromatography (1:1 EtOAc:Hex) provided 20.5g pure malonate adduct (compound of formula IV where R*=R*=H, R’=Me, R!'= ethyl, and R'’=R"?=CO,Et), (83%), as a colorless solid, m.p. 122-123°C; 'H NMR (400 MHz, CDCl;)3: 8.38 (d,J= 2.5 Hz, 1H),
8.19 (dd, J= 1.5, 4.6 Hz, 1H), 8.16 (d, J= 2.4 Hz, 1H), 7.47 (dd, J= 1.5, 8.0 Hz, 1H), 7.09 ’ (dd, J=4.7, 8.0 Hz, 1H), 4.56 (s, 1H), 4.20 (m, 6H), 3.49 (s, 3H), 1.25 (t, J= 7.1 Hz, 9H). '3C NMR (100 MHz, CDCl3)8: 167.30 (s), 167.23 (s), 159.31 (s), 154.50 (s), 151.18 (d), ’ 144.34 (d), 141.93 (d), 131.63 (s), 130.74 (d), 123.52 (s), 120.57 (s), 119.78 (d), 62.17 (1), 54.80 (d), 41.24 (1), 37.30 (q), 13.96 (q), 13.58 (q). Anal. Calcd for C31H24N4Os: C, 61.15;
H, 5.87; N, 13.58. Found: C, 61.14; H, 5.66; N, 13.51.
Example 3: Arylation of Isopropylcyanoacetate and Formation of Compound of
Formula V where R’=R‘=H, R°=Me, R''= ethyl, and R"’=CO,H.
An inerted 800 L reactor was charged with 12.0 Kg 60% NaH/oil (300 mol, 2.5 eq.), 0.27
Kg Pd(OAc); (1.2 mol, 0.01 eq.), 1.26 Kg PPh; (4.8 mol, 0.04 eq.), and 40 Kg tricyclic bromide (compound of formula II where R?>=R*=H, R*=Me, R''= ethyl, and X= Br; 120 mol, 1 eq.). The reactor was again inerted, then 70 Kg of PhMe was charged, and the mixture heated to 60°C. To this mixture was then added a solution of 17.4L cyanoisopropylacetate (138 mol, 1.15 eq.) in 20L PhMe via metering pump at a fixed rate over 2 hours (Caution: H, gas evolution). The reactor contents were then heated to 100°C and maintained there for 1.5 hours. HPLC of an aliquot showed the arylation was complete to compound of formula IV where R’=R*=H, R’=Me, R''= ethyl, R'*=CN and
R"=CO0,iPr. The mixture was then cooled to 35°C and quenched by the addition of 19 Kg isopropanol (308 mol, 2.6 eq.) over 20 minutes (Caution: H; gas evolution). 438 Kg IM
NaOH solution ( 417 mol, 3.5 eq.) was then added, and the mixture heated to 80°C and maintained there for 8 hours. HPLC of an aliquot showed the hydrolysis was complete to the desired carboxylic acid. The mixture was cooled to 25°C and the phases separated.
The upper phase was discarded to waste, while the lower aqueous phase was returned to the reactor. 218 Kg EtOAc was then charged and the mixture agitated for 15 minutes, then the phases were allowed to separate. The lower aqueous phase was returned to the reactor 3 and cooled to 10°C. To this mixture was then slowly added 6N H,SO4 with continuous monitoring of pH until a final pH of 3.3 was achieved: this required 133 Kg of H,SO4 : solution. The resulting slurry was then warmed to 25°C and maintained there for 1 hour.
The batch was then centrifuged and washed twice with 40 Kg H,0. The solid was then dried at full vacuum at 40°C until LOD <1% to give 36.0 Kg of the carboxylic acid
(compound of formula V where R’=R*=H, R’>=Me, R''= ethyl, and R"°=CO,H; 96%), as an off white solid. Mp 226-228°C; 'H NMR (500MHZ, DMSO)é: 12.47 (s, 1H), 8.32 (d, \ J=2.0 Hz, 1H), 8.20 (dd, J= 4.6, 1.5 Hz, 1H), 7.96 (d, J= 2.3 Hz, 1H), 7.81 (dd, J= 8.0, 1.6 Hz, 1H), 7.24 (m, J= 4.6, 8.0 Hz, 1H), 4.08 (q, J= 7.0 Hz, 2H), 3.63 (5, 3H), 3.43 (s, 3H), 1.17 (t, J= 7.0Hz, 3H). >’C NMR (125 MHz, DMSO)é: 172.22 (s), 166.26 (5), 157.47 (s), 153.96 (s), 151.32 (d), 144.06 (d), 141.59 (d), 131.72 (d), 131.14 (s), 126.01 (s), 120.28 (d), 120.12 (s), 40.45 (t), 36.74 (q), 36.34 (t), 13.42 (q). Anal. Calcd for
C16H6N4O3: C, 61.53; H, 5.16; N, 17.94. Found: C, 61.28; H, 4.94; N, 17.56.
Example 4: Arylation of Methylphenylsulfonyl acetate: Formation of Compound of
Formula IV where R’=R*=H, R*=Me, R!'= ethyl, R'">=C0,Me and R"”=SO,Ph.
A flask was charged with 165 mg Pd dba; (0.18 mmol, 0.02 eq.), 577 mg triphenylphosphine (2.2 mmol, 0.12 eq.), and 45 mL 1,4-dioxane. After stirring in an inert atmosphere for 15 minutes, 647 mg NaH (27 mmol, 3 eq.) was added in portions. To this 1S mixture was then added 3.00g tricyclic bromide (compound of formula II where R*=R*=H,
R’=Me, R''= ethyl, and X= Br; 9.00 mmol, 1 eq.), followed by 2.50 g (11.7 mmol, 1.3 eq.) of methylphenylsulfonyl acetate. The mixture was then heated at 60°C for 18h, cooled to ambient temperature and quenched by the addition of 0.5 mL H,O. The dioxane was removed in vacuo to give the crude product as a grey solid, 3.5g (~90%). NMR and MS indicated the desired arylation product (Compound of Formula IV where R’=R*=H,
R’=Me, R''= ethyl, R'>=CO,Me and R"’=SO.Ph).
Example 5: Arylation of Diethylphosphonyl acetonitrile: Formation of Compound of Formula IV where R?=R‘=H, R*=Me, R''= ethyl, R">=CN and R"=P(O)(OEt)..
A flask was charged with 1.00g tricyclic bromide (compound of formula II where
R2=R‘=H, R’=Me, R''= ethyl, and X= Br; 3.00 mmol, 1 eq.), 55 mg Pd,dba; (0.06 mmol, . 0.02 eq.), 95 mg triphenylphosphine (0.36 mmol, 0.12 eq.), and 0.69 diethylphosphonyl acetonitrile (3.90 mmol, 1.3 eq.). To this mixture was then added 15 mL 1,4-dioxane, : followed by 216 mg NaH (9.00 mmol, 3 eq.). The resulting mixture was then heated at 70°C for three hours. The mixture was cooled to ambient temperature and quenched by the cautious addition of 25 mL H,0, and 20 mL dichloromethane was added. The pH was then adjusted to 2.5 with IN aq.
HC! and diluted with additional H,O (25 mL) and ‘ dichloromethane (25 mL). The phases were then separated and the organic phase concentrated to a brown oil.
The oil was then triturated with 10 mL t-butylmethyl ether to give a precipitate of the product, which was filtered to give 0.95g product as an off white solid.
NMR and MS indicated the desired arylation product (Compound of Formula IV where R*=R*=H, R*~Me, R''= ethyl, R'’=CN and R"’=P(O)(OEt),).
Claims (3)
- What is claimed is:l. A process for making a compound of the formula I: RY o RY \ N 6 = IAN 0 3 / 8 ~ \2 7 N 102 Q N N 2 R Rr 5 0); wherein: R? is selected from the group consisting of H, F, Cl, C4 alkyl, C34 cycloalkyl and CFs; R*is H or Me; R®is H, Me or Et, with the proviso that R* and R® are not both Me, and if R* is Me then R® cannot be Et; R'! is Me, Et, cyclopropyl, propyl, isopropyl, or cyclobutyl; and Q is selected from the group consisting of: 4 [ _ P and — Ny _ —N+ oO So is which process comprises the following steps: (a) reacting a starting compound of the formula IIR} A 7 ; N \ VY — R? N 1, " R (11)wherein RZ, RY, R> and R'! are as hereinbefore defined with respect to the compound of the s formula I and wherein X is a chlorine, iodine, or bromine, or a fluorosulfonate moiety selected from the group consisting of OSO,F and -OS0,(CF;),CF3 wherein n is an integer between 0 and 10, with a malonate or malonate surrogate of the formula III12 13 RNA (110)wherein, R'? is a cyano group or a group of the formula —COOR'", wherein R" is a C-4-alkyl group, a C-j4-alkyloxy-C-14-alkyl group group phenyl, naphthyl, thiophenyl, furyl,pyridyl, imidazole or benzyl, and R" isa cyano group, a group of the formula -COOR'® (wherein R"? is a C-)4-alkyl group, a C-14-alkyloxy-C-14-alkyl group group phenyl, naphthyl, thiophenyl, furyl, pyridyl, imidazole or benzyl), a group of the formula -SO,R'® (wherein R'® is a C-.4-alkyl group, phenyl, furyl, pyridyl or benzyl), a group of the formula -P(O)(OR""), (wherein R"is phenyl, furyl or pyridyl) or a group of the formula -SOR'® (wherein R'® is a C-; s-alkyl) group, a C-14-alkyloxy-C-;4-alkyl group group phenyl, naphthyl, thiophenyl, furyl, pyridyl, imidazole or benzyl),in an organic solvent, in the presence of a palladium catalyst, a suitable ligand and strong ‘ base, to yield an intermediate of the formula IV RY 0 4 R \ R'2 ow ha VY, — NY R R' IV) wherein R?, R, R, R! ! R'? and RP" are as hereinbefore defined in this claim; (b) reductively cleaving the sulfur or phosphorus-containing group, if the intermediate of the formula IV contains a sulfur or phosphorus-containing group;(c) hydrolyzing the intermediate of the formula IV to yield a further intermediate of the formula V RY 0) RG \ N \ BD I we VY — NN R R' (V) wherein R?, R®, RS and R"! are as hereinbefore defined in this claim and R" is -COOH or, if the reactant of formula III was a malonate and mild hydrolysis conditions are employed, wherein R'® may additionally be a group of the formula -COOR'* wherein R' is as . hereinbefore defined in this claim; : (d) reducing the carboxylic acid or ester intermediate of the formula V to yield an alcohol of the formula VIRY 0 R} \ N jot | ) > \ V/ — N NN R rR" (VD wherein R?, R* R® and R'! are as hereinbefore defined in this claim; and ©) condensing the alcohol of formula VI with a reactant of the formula HO HO HO " { SR —N —N - ~ , , 0 or o to yield the final product of the formula I.
- 2. A process for making a compound of the formula IV RY 0 4 R \, R'2 ~I / NN rR" \ ZN N= 2 N R Rr" (IV). wherein: : R? is selected from the group consisting of H, F, Cl, Cy_4 alkyl, C34 cycloalkyl and CFs, : 15 R*is Hor Me, R® is H, Me or Et, with the proviso that R* and R? are not both Me, and if R* is Me then rR’ cannot be Et,R'is Me, Et, cyclopropyl, propyl, isopropyl, or cyclobutyl, R'? isa cyano group or a group of the formula —COOR", wherein R'is a C-j4-alkyl group, a C-j4-alkyloxy-C-4-alkyl group group phenyl, naphthyl, thiophenyl, furyl, . pyridyl, imidazole or benzyl, and s R” isa cyano group, a group of the formula -COOR'? (wherein R" is a C-14-alkyl group, a C-j4-alkyloxy-C-,4-alky! group group phenyl, naphthyl, thiophenyl, furyl, pyridyl, imidazole or benzyl), a group of the formula -SO2R'® (wherein R'® is a C-1.q-alkyl group, phenyl, furyl, pyridyl or benzyl), a group of the formula -P(O)(OR"7), (wherein R" is phenyl, furyl or pyridyl) or a group of the formula -SOR'® (wherein R'® is a C-4-alkyl group, a C-14-alkyloxy-C-;.4-alkyl group group phenyl, naphthyl, thiophenyl, furyl, pyridyl, imidazole or benzyl), which process comprises the following steps: (a) reacting a starting compound of the formula IIRY 0 RG \ N = NN X \ V7, — NN R Rr" (IT)wherein R%, RY, R’ and R'! are as hereinbefore defined in this claim and wherein X is a chlorine, iodine, or bromine, or a fluorosulfonate moiety selected from the group consisting of -OSO,F and -OSO,(CF2),CF3 wherein n is an integer between 0 and 10,with a malonate or malonate surrogate of the formula III : R" R" ~~ my wherein,R'? isa cyano group or a group of the formula -COOR", wherein R'* is a C-)4-alkyl group, a C-)s-alkyloxy-C- 4-alkyl group group phenyl, naphthyl, thiophenyl, furyl, pyridyl, imidazole or benzyl, and R"? isa cyano group, a group of the formula -COOR" (wherein R" is a C-j.+-alkyl group, a C-14-alkyloxy-C-|4-alkyl group group phenyl, naphthyl, thiophenyl, furyl, pyridyl, imidazole or benzyl), a group of the formula -SO,R'S (wherein R'¢ is a C-;.4-alky! group, phenyl, furyl, pyridyl or benzyl), a group of the formula -P(O)(OR'""), (wherein RY is phenyl, fury! or pyridyl) or a group of the formula -SOR'® (wherein R'% is a C-j4-alkyl group, a C-)4-alkyloxy-C-4-alkyl group group phenyl, naphthyl, thiophenyl, furyl, pyridyl, imidazole or benzyl), in an organic solvent, in the presence of a palladium catalyst, a suitable ligand and strong base, to yield the compound of the formula IV.
- 3. A process for making a compound of the formula V RY o RE N == AN \ ) / Rr" — NN R Rr" Vv) wherein: : RZ is selected from the group consisting of H, F, Cl, C4 alkyl, C34 cycloalkyl and CF3; R*is H or Me; . RS is H, Me or Et, with the proviso that R* and R® are not both Me, and if R* is Me then R’ cannot be Et; R!! is Me, Et, cyclopropyl, propyl, isopropyl, or cyclobutyl; and
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39197902P | 2002-06-28 | 2002-06-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200409091B true ZA200409091B (en) | 2005-05-19 |
Family
ID=35161208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200409091A ZA200409091B (en) | 2002-06-28 | 2004-11-10 | Process and intermediates for making non-nucleoside HIV-1 reverse transcriptase inhibitors. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200409091B (en) |
-
2004
- 2004-11-10 ZA ZA200409091A patent/ZA200409091B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6943255B2 (en) | Process for imidazo[4,5-c]pyridin-4-amines | |
US7153967B2 (en) | Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin-4-phthalimide intermediates | |
EP2134710B1 (en) | Substituted heterocycle fused gamma-carbolines synthesis | |
KR101440257B1 (en) | Process for the manufacture of intermediates for preparing pharmaceutically active compounds | |
CA2616984A1 (en) | Asymmetric catalytic reduction of oxcarbazepine | |
CN106831737B (en) | Preparation of vipatavir and derivatives thereof | |
CN111315742A (en) | Improved process for preparing aminopyrimidine derivatives | |
KR20130122709A (en) | Method of synthesis of ferroquine by convergent reductive amination | |
US6759533B2 (en) | Process and intermediates for making non-nucleoside HIV-1 reverse transcriptase inhibitors | |
KR20130089157A (en) | Novel processes | |
ZA200409091B (en) | Process and intermediates for making non-nucleoside HIV-1 reverse transcriptase inhibitors. | |
CN102675125B (en) | Simple, convenient and high-efficiency synthesis method of 4-chloro-2-trifluoroacetylaniline and analogs thereof | |
IL271974B (en) | Novel intermediates useful for the synthesis of aminopyrimidine derivatives, process for preparing the same, and process for preparing aminopyrimidine derivatives using the same | |
US7459467B2 (en) | Manufacturing process for methyl phenidate and intermediates thereof | |
CN113444041A (en) | Method for synthesizing polysubstituted quinoline compound through photocatalysis | |
KR20050024424A (en) | Process and intermediates for making non-nucleoside HIV-1 reverse transcriptase inhibitors | |
CN114848648B (en) | Application of C-6-position arylation deazapurine derivative in preparation of antitumor drugs | |
US20110245503A1 (en) | Enantioselective synthesis of asymmetric beta-carboline intermediates | |
CN114957262B (en) | Preparation method of C-6-position arylation deazapurine derivative | |
JP2011519919A (en) | Catalytic process for asymmetric hydrogenation | |
CN101429160A (en) | Synthesis of 1-R-4-amino-1,2,3,4-tetrahydroquinoline | |
CN117486782A (en) | N-substituted carbazole derivative and preparation method and application thereof | |
US20040030134A1 (en) | Process for preparation of integrin receptor antagonist intermediates | |
KR20010029673A (en) | Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4h-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein | |
WO2003072042A2 (en) | Malonate-claisen rearrangement for preparation of integrin receptor antagonist intermediates |